Surgical Management of Breast Cancer Liver Metastasis

Amir A Rahnemai-Azar; Luke V Selby; Maryam B Lustberg; Timothy M Pawlik

doi:10.1016/j.hoc.2024.08.012

Surgical Management of Breast Cancer Liver Metastasis

Hematol Oncol Clin North Am. 2025 Feb;39(1):25-35. doi: 10.1016/j.hoc.2024.08.012.

Authors

Amir A Rahnemai-Azar¹, Luke V Selby², Maryam B Lustberg³, Timothy M Pawlik⁴

Affiliations

¹ Department of Surgery, Division of Surgical Oncology, California University of Science and Medicine, Colton, CA 92324, USA.
² Department of Surgery, Division of Surgical Oncology, The Ohio State University Medical School, Columbus, OH 43210, USA.
³ Department of Medicine, Division of Medical Oncology, The Ohio State University Medical School, Columbus, OH 43210, USA.
⁴ Department of Surgery, Division of Surgical Oncology, The Ohio State University Medical School, Columbus, OH 43210, USA. Electronic address: tim.pawlik@osumc.edu.

PMID: 39510675
DOI: 10.1016/j.hoc.2024.08.012

Abstract

Hepatic resection for patients with isolated breast cancer liver metastases (BCLM) is associated with prolonged disease-free interval and better overall survival in highly selected patients. Patients with limited disease who are not candidates for surgery benefit from ablative therapies for isolated breast cancer metastasis in addition to systemic chemotherapy. In the era of modern effective systemic chemotherapy for BCLM, local regional therapies are warranted, yet only in well-selected patients following discussion in a multidisciplinary setting. This article reviews data related to hepatic resection and ablative therapies of BCLM, as well as long-term outcomes of women treated with these approaches.

Keywords: Breast cancer liver metastasis; Liver metastasectomy; Liver resection; Metastatic breast cancer.

Publication types

Review

MeSH terms

Breast Neoplasms* / pathology
Breast Neoplasms* / surgery
Disease Management
Female
Hepatectomy* / methods
Humans
Liver Neoplasms* / secondary
Liver Neoplasms* / surgery
Treatment Outcome